Research programme: Huntington's disease therapeutics - CHDI/ENKAM Pharmaceuticals

Drug Profile

Research programme: Huntington's disease therapeutics - CHDI/ENKAM Pharmaceuticals

Alternative Names: Dekafin 1; FGF receptor agonists - CHDI/ENKAM; HD programme - CHDI/ENKAM; Huntington's disease programme - CHDI/ENKAM

Latest Information Update: 27 Feb 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ENKAM Pharmaceuticals A/S
  • Developer CHDI; ENKAM Pharmaceuticals A/S
  • Class Peptides
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Huntington's disease

Most Recent Events

  • 27 Feb 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top